Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
2 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Tectonic Therapeutic, Inc.’s names, not what it holds today.
Patents granted
2
2 utility, 1976 to Dec 31, 2025
Granted in 2025
2
in the last year the record reads
Applications published
10
1 of them in 2025
Names they are printed under
4
a former name, a subsidiary, its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals1
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
AvroBio, Inc. a former name
named as the applicant on its applications, in US
7 publishedTectonic Operating Company, Inc. a subsidiary
US, as the owner printed on each patent
0 publishedTectonic Therapeutic, Inc. its own name
named as the applicant on its applications, in US
2 publishedTECTONIC OPERATING COMPANY, INC. a subsidiary
named as the applicant on its applications, in US
1 publishedNames not counted (1)
AvroBio, Inc.
Most of its patents print GB; this name counts in US. 0 granted and 2 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 30, 2025 | 2025/0333467 | RELAXIN-2 FUSION PROTEIN ANALOGS AND METHODS OF USING SAME | Pharmaceuticals | TECTONIC OPERATING COMPANY, INC. |
| Dec 12, 2024 | 2024/0409601 | RELAXIN-2 FUSION PROTEIN ANALOGS AND METHODS OF USING SAME | Pharmaceuticals | Tectonic Therapeutic, Inc. · patent 12,264,188 granted from it |
| Oct 3, 2024 | 2024/0325506 | COMPOSITIONS AND METHODS FOR TREATMENT OF GAUCHER DISEASE | Pharmaceuticals | AvroBio, Inc. |
| Dec 28, 2023 | 2023/0414725 | COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASE | Biotechnology | AvroBio, Inc. |
| Oct 26, 2023 | 2023/0340058 | RELAXIN-2 FUSION PROTEIN ANALOGS AND METHODS OF USING SAME | Biotechnology | Tectonic Therapeutic, Inc. · patent 12,509,497 granted from it |
| Oct 12, 2023 | 2023/0322897 | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS | Pharmaceuticals | AvroBio, Inc. |
| May 5, 2022 | 2022/0133850 | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS | Pharmaceuticals | AvroBio, Inc. |
| May 5, 2022 | 2022/0133808 | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS | Pharmaceuticals | AvroBio, Inc. |
| Apr 14, 2022 | 2022/0111005 | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS | Pharmaceuticals | AvroBio, Inc. |
| Jan 7, 2021 | 2021/0000929 | COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Pharmaceuticals | AvroBio, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 3.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.